China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S
03320: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$9.60 | Pvdqck | Qqvthcnd |
CR Pharma Earnings: Mixed Segment Results; Shares Fairly Valued
Narrow-moat CR Pharma's interim revenue growth is slower than expected, but offset by a higher gross margin due to product mix. We tweak our 2024 annual assumptions accordingly while keeping our long-term outlook unchanged. Our fair value estimate remains at HKD 5.80 per share. We think the share price is fairly valued.